Some of the leaders in the frenzied late-stage race to develop a PCSK9 drug watched their stock prices stumble on Friday afternoon as word of the FDA's concern about potential neurocognitive side effects in the cholesterol drug class ripped through Twitter.
As the biosimilar market takes shape, companies are gunning to produce copies of some of the world's top-selling drugs. And according to a new Moody's report, with their star products wearing targets on their backs, AbbVie, Amgen and Roche are most exposed to the new competition.
At Merck, the already giant-sized hope that its cancer immunotherapy program for the PD-1 drug MK-3475 represents just swelled significantly in importance. Just ahead of its 2013 earnings report Wednesday, the pharma giant announced plans to tie up with a trio of major league biopharma partners to launch a whole new slate of combination studies that could significantly extend its reach in the oncology market.
Amgen reported a 30% leap in fourth-quarter profits this week, but that is still not enough to save more than 200 jobs at the company's Epogen production operations in Colorado, which were targeted earlier as long-term sales of its anemia franchise have tapered off.
Amgen is batting 1.000 in its ambitious clinical program for the promising PCSK9 cholesterol drug evolocumab (AMG-145), unveiling a 5th successful Phase III study as it prepares for an FDA application that could give it first-mover status in a blockbuster field.
A pair of cross-continent Big Biotechs came up big this week in the revenue department, with hefty sales powering both Biogen Idec and Amgen to double-digit fourth-quarter earnings increases.
Amgen marched through yet another Phase III study for the closely watched PCSK9 cholesterol drug evolocumab (AMG-145), racking up more promising data for one of the biggest late-stage programs in the business.
Amgen's promising PCSK9 candidate cleared another Phase III hurdle, this time in statin-intolerant patients, as the company piles up positive data with hopes of taking the lion's share of what could be a multibillion-dollar market.
Two people were injured in an explosion at Amgen's South San Francisco research lab earlier this week, according to several reports. The blast was the second to occur at the facility in the past in 9 months.
California's Atara Biotherapeutics has heaped more cash onto its second funding round, giving the Amgen spinoff $52 million in Series B funds to support its programs in kidney disease and oncology.